Mastercard Inc
Change company Symbol lookup
Select an option...
MA Mastercard Inc
ABBV Abbvie Inc
BABA Alibaba Group Holding Ltd
OBMP OncBioMune Pharmaceuticals Inc
AVNW Aviat Networks Inc
AMPY Amplify Energy Corp
JEPI JPMorgan Equity Premium Income ETF
VOLAF Volvo AB
AGNC Agnc Investment Corp
GME GameStop Corp
Go

Information Technology : IT Services | Large Cap Growth
Company profile

Mastercard Incorporated is a technology company that connects consumers, financial institutions, merchants, governments and businesses across the world, enabling them to use electronic forms of payment. The Company allows user to make payments by creating a range of payment solutions and services using its brands, which include MasterCard, Maestro and Cirrus. The Company provides a range of products and solutions that support payment products, which customers can offer to their cardholders. The Company's services facilitate transactions on its core network among account holders, merchants, financial institutions, businesses, governments and other organizations in markets globally. The Company's products include consumer credit, consumer debit, prepaid and commercial. It also provides integrated offerings such as cyber and intelligence products, information and analytics services, consulting, loyalty and reward programs and processing solutions.

Closing Price
$386.17
Day's Change
-0.32 (-0.08%)
Bid
--
Ask
--
B/A Size
--
Day's High
389.10
Day's Low
383.67
Volume
(Average)
Volume:
2,725,766

10-day average volume:
2,817,748
2,725,766

Ocugen to Host Conference Call on Thursday, March 18 at 8:30 a.m. ET to Discuss 2020 Financial Results and Provide a Business Update

5:45 pm ET March 12, 2021 (Globe Newswire) Print

Ocugen, Inc.("Ocugen") (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its 2020 financial results and provide a business update at 8:30 a.m. ET on Thursday, March 18, 2021.

Ocugen will issue a pre-market earnings announcement the same day. Investors are invited to participate on the call using the following details:

 Dial-In Number: (844) 873-7330 (U.S.) or (602) 563-8473 (international)
 Conference ID:  ID 2375087
 Webcast:        Available in the "Investors" section of the Ocugen website by clicking here and archived for approximately 45 days following the call

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug -- "one to many" and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech International Limited's COVAXIN(TM) vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission ("SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:

Ocugen, Inc.

Sanjay Subramanian

Chief Financial Officer and Head of Corporate Development

IR@Ocugen.com

Media Contact:

LaVoieHealthScience

Emmie Twombly

etwombly@lavoiehealthscience.com

+1 857-389-6042

https://ml.globenewswire.com/media/163cce64-f2fe-4170-bdba-c5b9826bb921/small/ocugen-logo-color-png.png

https://ml.globenewswire.com/media/163cce64-f2fe-4170-bdba-c5b9826bb921/small/ocugen-logo-color-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.